Miriana Quaranta

Ms. Miriana Quaranta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGMichela Guida
Michela Guida
CTCHIARA TAMMARO
CHIARA TAMMARO
MQMiriana Quaranta
Miriana Quaranta
BSBenedetta Salvucci
Benedetta Salvucci
Mariangela BiavaMariangela Biava
Mariangela Biava
SCSara Consalvi
Sara Consalvi
According to the latest World Health Organization (WHO) report, an estimated 10.6 million people were diagnosed with tuberculosis (TB) in 2022, and 1.30 million died. A major concern is the emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains, fueled by the length of anti-TB treatment and HIV comorbidity. Innovative anti-TB agents acting with new modes of action are the only solution to counteract the spread of resistant infections. To escape starvation and survive inside macrophages, Mtb has evolved to become independent of the host by synthesizing its own amino acids. Therefore, targeting amino acid biosynthesis could subvert the ability of the mycobacterium to evade the host immune system, providing innovative avenues for drug discovery. The aim of this review is to give an overview of the most recent progress in the discovery of amino acid biosynthesis inhibitors. Among the hits discovered over the past five years, tryptophan (Trp) inhibitors stand out as the most advanced and have significantly contributed to demonstrating the feasibility of this approach for future TB drug discovery. Future efforts should be directed at prioritizing the chemical optimization of these hits to enrich the TB drug pipeline with high-quality leads.

24 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Fabio ScarpaFabio Scarpa
Fabio Scarpa
Francesco BrandaFrancesco Branda
Francesco Branda
Giancarlo CeccarelliGiancarlo Ceccarelli
Giancarlo Ceccarelli
CRChiara Romano
Chiara Romano
Chiara LocciChiara Locci
Chiara Locci
Daria SannaDaria Sanna
Daria Sanna
Recombination, a process of genetic exchange between distinct organisms, has played a critical role in the emergence of SARS-CoV-2 variants such as the XEC recombinant. This study provides a detailed genomic and structural characterization of XEC, derived from the recombination of lineages KP.3.3 (donor) and KS.1.1 (acceptor). Phylogenomic analyses reveal that XEC and its descendant XEC.1 form a monophyletic clade with close evolutionary ties to KP.3.3. The genomic breakpoint, spanning nucleotide positions 22,363–22,463, marks the shift from KS.1.1 to KP.3.3 within the spike protein gene. Mutational analysis highlights shared traits with its parental lineages, including mutations associated with immune evasion, receptor affinity, and fusogenicity. Notable changes, such as Q493E and L455S, may confer unique immunogenic properties, though XEC’s overall immune escape potential is limited by the absence of new mutations in conserved epitopes. Despite these mutations, XEC demonstrates restricted geographical spread, low genetic variability, and an evolutionary trajectory indicative of an evolutionary dead-end. Bayesian Skyline Plot analysis corroborates this, showing stable but declining population size. These findings underscore the need for ongoing genomic surveillance to monitor recombinant variants’ characteristics and public health impact. This study contributes to understanding viral evolution and highlights the importance of distinguishing variants of concern from those with minimal epidemiological significance.

Verified
Journal Article
Open access
PDF file
Fabio ScarpaFabio Scarpa
Fabio Scarpa
Ilenia AzzenaIlenia Azzena
Ilenia Azzena
ACAlessandra Ciccozzi
Alessandra Ciccozzi
Marta GiovanettiMarta Giovanetti
Marta Giovanetti
Chiara LocciChiara Locci
Chiara Locci
MCMassimo Ciccozzi
Massimo Ciccozzi
The XBB.1.16 SARS-CoV-2 variant, also known as Arcturus, is a recent descendant lineage of the recombinant XBB (nicknamed Gryphon). Compared to its direct progenitor, XBB.1, XBB.1.16 carries additional spike mutations in key antigenic sites, potentially conferring an ability to evade the immune response compared to other circulating lineages. In this context, we conducted a comprehensive genome-based survey to gain a detailed understanding of the evolution and potential dangers of the XBB.1.16 variant, which became dominant in late June. Genetic data indicates that the XBB.1.16 variant exhibits an evolutionary background with limited diversification, unlike dangerous lineages known for rapid changes. The evolutionary rate of XBB.1.16, which amounts to 3.95 × 10−4 subs/site/year, is slightly slower than that of its direct progenitors, XBB and XBB.1.5, which have been circulating for several months. A Bayesian Skyline Plot reconstruction suggests that the peak of genetic variability was reached in early May 2023, and currently, it is in a plateau phase with a viral population size similar to the levels observed in early March. Structural analyses indicate that, overall, the XBB.1.16 variant does not possess structural characteristics markedly different from those of the parent lineages, and the theoretical affinity for ACE2 does not seem to change among the compared variants. In conclusion, the genetic and structural analyses of SARS-CoV-2 XBB.1.16 do not provide evidence of its exceptional danger or high expansion capability. Detected differences with previous lineages are probably due to genetic drift, which allows the virus constant adaptability to the host, but they are not necessarily connected to a greater danger. Nevertheless, continuous genome-based monitoring is essential for a better understanding of its descendants and other lineages.

17 July 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
Fabio ScarpaFabio Scarpa
Fabio Scarpa
Chiara LocciChiara Locci
Chiara Locci
Ilenia AzzenaIlenia Azzena
Ilenia Azzena
Marco CasuMarco Casu
Marco Casu
PFPier Luigi Fiori
Pier Luigi Fiori
Daria SannaDaria Sanna
Daria Sanna
Recombination events are very common and represent one of the primary drivers of RNA virus evolution. The XBF SARS-CoV-2 lineage is one of the most recently generated recombinants during the COVID-19 pandemic. It is a recombinant of BA.5.2.3 and BA.2.75.3, both descendants of lineages that caused many concerns (BA.5 and BA.2.75, respectively). Here, we performed a genomic survey focused on comparing the recombinant XBF with its parental lineages to provide a comprehensive assessment of the evolutionary potential, epidemiological trajectory, and potential risks. Genetic analyses indicated that although XBF initially showed the typical expansion depicted by a steep curve, causing several concerns, currently there is no indication of significant expansion potential or a contagion rate surpassing that of other currently active or previously prevalent lineages. BSP indicated that the peak has been reached around 19 October 2022 and then the genetic variability suffered slight oscillations until early 5 March 2023 when the population size reduced for the last time starting its last plateau that is still lasting. Structural analyses confirmed its reduced potential, also indicating that properties of NTDs and RBDs of XBF and its parental lineages present no significant difference. Of course, cautionary measures must still be taken and genome-based monitoring remains the best tool for detecting any important changes in viral genome composition.

9 June 2025 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Open access
MQMiriana Quaranta
Miriana Quaranta
AVAllegra Via
Allegra Via
SPStefano Pascarella
Stefano Pascarella
Since its first appearance in China, the molecular evolution of SARS‐CoV‐2 has progressed through altering the properties of the Spike protein, changing the virus ability to transmit and to evade host immune surveillance. Despite receiving less attention than the Receptor Binding Domain (RBD), the Spike N‐Terminal Domain (NTD) is crucial to SARS‐CoV‐2 biology and pathogenesis. This study provides a comparative structural analysis of the NTD from the wild‐type strain and different variants (BA.2, XBB.1, XBB.1.5, BA.2.86, JN.1, HV.1, KP.2, KP.3, and KP.3.1.1), aiming to clarify the structural impact of mutations in each variant. To assess the impact of mutations on the interaction of NTD with antibodies, we selected as a test case the neutralizing antibody 4A8, which has proven highly effective against the WT. The results obtained from molecular dynamics simulations, surface electrostatic potential analysis, and binding energy predictions show a clear trend in the evolution of the virus. The net charge of the NTD decreases as the variants progress, reaching a minimum charge of −1.84 observed for KP.3.1.1. This is in clear contrast to the RBD net charge, which follows an opposite trend toward higher positive values. Binding energy predictions show that the antibody's efficacy decreases as the virus evolves. While the WT exhibited an interaction energy of −96.28 kcal/mol with 4A8, more recent variants like KP.3 show no interaction stronger than −64.00 kcal/mol. These results reveal a clear trend of modifications aimed at favoring immune escape in the virus' evolutionary trajectory.

20 July 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
MQMiriana Quaranta
Miriana Quaranta
ACAlessandra Ciccozzi
Alessandra Ciccozzi
Francesco BrandaFrancesco Branda
Francesco Branda
LSLeonardo Sernicola
Leonardo Sernicola
MCMassimo Ciccozzi
Massimo Ciccozzi
Fabio ScarpaFabio Scarpa
Fabio Scarpa
In November 2024, a highly mutated descendant of the Omicron BA.3 subvariant, designated BA.3.2, emerged in South Africa carrying 39 spike mutations, two large N-terminal domain (NTD) deletions and a novel four-amino acid insertion. A key feature of BA.3.2 is extensive NTD remodeling, including a major deletion spanning residues 135–148 affecting the β-hairpin region and contributing to the loss of most of the N1 loop. This study compares the evolutionary dynamics and structural features of BA.3.2 with BA.3. Phylodynamic analyses show that BA.3 underwent early demographic stability followed by a decline in genetic diversity, consistent with limited circulation, whereas BA.3.2 displays recent emergence and a progressive reduction in effective population size without rapid expansion. Selection analyses indicate BA.3 evolution is mainly driven by changes in the receptor-binding domain, while BA.3.2 shows dispersed signals across spike regions, including codon 1162. Structural and molecular dynamic analyses reveal increased flexibility and a broader conformational landscape in the BA.3.2 NTD, driven by the deletion and resulting loss of stabilizing interactions. Overall, BA.3.2 follows a distinct evolutionary trajectory characterized by antigenic remodeling of the spike NTD, underlining the need for continued surveillance of emerging SARS-CoV-2 descendant lineages.